CERS Stock Forecast: Cerus Corp. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Cerus Corp. hold a median 12-month price target of $5 — +170.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 96 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cerus Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (89): Sales and profits are climbing, and climbing faster than before.
Volatility (37): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CERS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CERS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +170.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | Freedom Broker | Initiates | Buy | $6.50 |
| 1 May 2026 | BTIG | Upgrade | Buy | $4.00 |
| 21 Feb 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 17 Oct 2024 | Stifel | Maintains | Buy | — |
| 3 May 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 12 Apr 2024 | Craig-Hallum | Initiates | Buy | — |
| 7 Mar 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 6 Mar 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 Nov 2023 | Cantor Fitzgerald | Assumes | Overweight | $9.00 → $3.00 |
| 20 Jan 2023 | BTIG | Downgrade | Neutral | — |
| 27 May 2020 | Stifel | Maintains | Buy | — |
| 16 Apr 2020 | Stephens & Co. | Maintains | Overweight | — |
| 26 Feb 2020 | BTIG | Initiates | Buy | — |
| 26 Feb 2020 | BTIG Research | Initiates | Buy | — |
| 13 Nov 2019 | BTIG | Upgrade | Buy | — |
| 13 Nov 2019 | BTIG Research | Upgrade | Buy | — |
| 28 Aug 2019 | Stifel | Initiates | Buy | — |
| 22 Apr 2016 | BTIG | Maintains | Buy | — |
| 22 Apr 2016 | BTIG Research | Maintains | Buy | — |
| 17 Dec 2015 | Wedbush | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CERS.
This page is one stock. Monday covers all of them.
CERS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CERS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cerus Corp. returned +24.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CERS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.7×
- Price / book
- 5.2×
- EV / EBITDA
- —
Cheaper than 52% of US stocks
Cheaper than 17% of US stocks
- Revenue growth (YoY)
- 9.5%
- Earnings growth (YoY)
- —
- Gross margin
- 51.4%
- Operating margin
- −1.1%
- Net margin
- −3.2%
Higher than 52% of US stocks
Higher than 64% of US stocks
Higher than 33% of US stocks
Higher than 27% of US stocks
- Return on equity
- −10.7%
- Return on assets
- −0.7%
- Dividend yield
- —
Higher than 36% of US stocks
Higher than 41% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cerus Corp. has a market value of $383.7M and an enterprise value of $402.2M.
Revenue in the twelve months to 30 June 2026: $221.6M. The latest quarter grew 9.5% year on year.
Net income over the same four quarters: −$6.8M, a −3.1% net margin.
Diluted earnings per share, trailing twelve months: −$0.03.
Free cash flow in the twelve months to 30 June 2026: −$1.8M, after $4.2M of capital spending.
forward P/E: 129.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Cerus Corp. employs 261 people — $849K of revenue per employee.
Data provided by Twelve Data
CERS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CERS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cerus Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CERS
What is the CERS stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Cerus Corp. have a median 12-month price target of $5, with estimates ranging from $4 to $6.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CERS stock a buy right now?
Of the 4 analysts covering Cerus Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cerus Corp. 96 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CERS?
As at 21 Nov 2026, Cerus Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).
Will CERS stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +170.3% from the last close, and Ticker Nerd's factor model ranks Cerus Corp. 96 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CERS stock forecast for 2030?
No analyst covering Cerus Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CERS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6.5 over the next 12 months.
How has CERS stock performed over the past year?
Cerus Corp. returned +24.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cerus Corp. do?
Cerus Corporation is a biomedical products company focused on blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform designed to help safeguard donated blood components intended for transfusion.
About Cerus Corp.
Cerus Corporation is a biomedical products company focused on blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform designed to help safeguard donated blood components intended for transfusion. Its current product line includes systems for platelets and plasma, and it also supports blood centers, hospitals, and other healthcare institutions that rely on treated blood products. Cerus Corporation operates within the healthcare and medical technology markets, with its products used to reduce the risk of blood-borne pathogens while preserving the therapeutic value of transfused components. Headquartered in Concord, California, Cerus Corporation is dedicated to advancing technologies that support safer blood supply workflows across clinical settings.
CEO Mr. Vivek K. Jayaraman · 261 employees · United States · https://www.cerus.com